SARS-CoV-2 ORF8 mediates signals in macrophages and monocytes through MyD88 independently of the IL-17 Receptor

Nicole O. Ponde[1], Karsen E. Shoger[2], Mst Shamima Khatun[3], Mrinal K. Sarkar[4], Ipsita Dey[1], Tiffany C. Taylor[1], Rylee N. Cisney[1], Samyuktha P. Arunkumar[1], Johann E. Gudjonsson[4], Jay K. Kolls[3], Rachel A. Gottschalk[2], Sarah L. Gaffen[1 *]

[1] Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh, Pittsburgh PA

[2] Department of Immunology, University of Pittsburgh, Pittsburgh PA

[3] Tulane University, New Orleans, LA

[4] Department of Dermatology, University of Michigan, Ann Arbor MI



Supplemental Fig. 1. A. IL-17RA and IL-17RC neutralizing Abs effectively block IL-17 signaling in stromal cells. ST2 murine stromal cells were pre-treated with IgG, anti-IL-17RA (left) or anti-IL-17RC (right) neutralizing Abs at 5 μg/mL for 1 h and stimulated with IL-17 (50 ng/mL) or ORF8 (1 μg/mL) for 3 h. Expression of *Il6* was quantified by qPCR normalized to *Gapdh*. Data are presented as fold-change relative to untreated cells, and show mean (± SEM). Each symbol represents a technical replicate (n=3).